Programs currently represented.
A live, anonymized index of in-licensing opportunities Vision Lifesciences is actively shopping to qualified buyers. Internal codes only; counterparty names, specific molecule identifiers, and economics disclosed bilaterally under NDA.
Late-stage ADC targeting HER2-low expressing solid tumors with differentiated payload chemistry. Phase 3 pivotal underway in three geographies with primary endpoint readout expected within 18 months.
Strong differentiation vs in-class; ex-China BD active.
Internal codes only.
Programs are listed under Vision Lifesciences internal codes. Counterparty names, specific molecule identifiers, and detailed economics are disclosed bilaterally under NDA after a qualified-buyer review.
Bilateral review before disclosure.
Briefs are released to pharmaceutical and biotech buyers whose therapeutic and territorial focus aligns with the asset. We screen for portfolio fit and competitive positions before sharing detailed materials.
Information barriers in place.
Where mandates touch overlapping therapeutic spaces, internal information barriers separate the engagement teams. We disclose potential conflicts in writing at first conversation and decline mandates we cannot run cleanly.
Request a confidential brief on any listed program.
Provide the VLS code(s) you are interested in, or describe the therapeutic profile you are sourcing for. A partner from the relevant desk will respond within one business day with NDA and, if appropriate, a confidential teaser.